Deborah Liben BA, JD

Deborah Liben began her career as outside counsel at Kaye Scholer LLP (now Arnold and Porter LLP) representing pharmaceutical companies in litigation involving off-label promotion and kickbacks allegations. After nearly a decade, Deborah joined the in-house legal team at Novartis Pharmaceuticals Corporation where she served as a strategic legal advisor for multiple hematology and oncology products and led the U.S. legal support for the first FDA-approved CAR T cell therapy. Deborah is currently Executive Director, Senior Corporate Counsel at Celgene Corporation, where she is the lead lawyer for Celgene’s CAR T cell therapy programs with bluebird bio and drives the legal strategy for various unique projects in preparation for commercialization.